Global Quit Smoking Drug Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are increasing across the globe. Medicine developed in order to help people stop smoking is referred to quit smoking drugs. The most frequently used quit smoking medications are nicotine replacement therapy (NRT). Some of the other examples of such medicines include Bupropion SR, Varenicline (also called Chantix), etc.
The factors that propel the growth of the Quit Smoking Drug Market include increasing demand, rapid urbanization & industrialization, and product development & technological innovations. In addition, factors such as large smoking population base, awareness among smokers regarding hazards of smoking, and growing disorders due to smoking significantly contributes to the market growth.
On the other hand, there are also factors that may hamper the growth of the market such as improper guidance of drug usage. Also, these medications can have a number of side effects such as irritability, restlessness, frustration, headache, feeling anxious, seizures, nausea, etc. Quit Smoking Drug Industry is classified on the basis of product type, applications, distribution channel and geography. Quit Smoking Drug Industry is segmented by product type as capsule, spray and others.
Quit Smoking Drug Market is classified on applications as hospital, medical center and others. Quit Smoking Drug Industry is segmented by distribution channel as online stores, specialty stores, pharmacies and others. Quit Smoking Drug Market is classified on the basis of geography as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa.
The North American region consists of the U.S., and Canada. Latin America region consists of Mexico and Brazil. The Western European region consists of Germany, Italy, France, England and Spain. The Eastern European region consists of Poland and Russia. Asia Pacific region consists of China, India, ASEAN, and Australia & New Zealand. The Middle East and African region consists of GCC, South Africa and North Africa. In case of geographical region, North America is projected to account a significant share in the Quit Smoking Drug Industry. Factors such as growing health consciousness and public awareness programs fuel the growth of this region.
Some of the key players that fuel the growth of the Quit Smoking Drug Market include Aradigm, Boots, BGP Group, Cambrex, Celtic Pharma, Cochrane Collaboration, Ceejay Healthcare, Johnson & Johnson, Roche, Sopharma, Zenara, and others. The key players are focusing on inorganic growth to sustain themselves amidst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.
This report studies Quit Smoking Drug in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
• BGP Group
• Cochrane Collaboration
• Ceejay Healthcare
• Celtic Pharma
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Quit Smoking Drug in these regions, from 2012 to 2022 (forecast), like
• North America
• Southeast Asia
Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
• Type I
• Type II
Split by application, this report focuses on consumption, market share and growth rate of Quit Smoking Drug in each application, can be divided into
• Medical Center
Research Support Specialist, USA